Table 2. Frequency and mean duration of antiretroviral medication use by HIV-infected participants (n=538).
| ARV medication | Percentage of participants having ever taken ARV medication | Mean duration of use of ARV medication in users (years) |
|---|---|---|
| HAART | 93.8 | 6.0 |
| NRTI (all) | 96.8 | 8.5 |
| PI (all) | 83.8 | 5.4 |
| NNRTI (all) | 70.3 | 3.6 |
| Lamivudine | 89.7 | 5.8 |
| Zidovudine | 80.2 | 4.6 |
| Stavudine | 63.7 | 4.0 |
| Tenofovir | 53.7 | 2.1 |
| Didanosine | 44.0 | 2.6 |
| Abacavir | 41.4 | 3.3 |
| Emtricitabine | 24.8 | 1.2 |
| Zalcitabine | 11.1 | 1.5 |
| Ritonavir | 58.0 | 3.6 |
| Indinavir | 43.5 | 3.3 |
| Nelfinavir | 40.0 | 2.9 |
| Lopinavir | 31.0 | 2.7 |
| Saquinavir | 27.3 | 3.7 |
| Atazanavir | 21.5 | 1.5 |
| Amprenavir | 9.3 | 1.9 |
| Fosamprenavir | 6.2 | 1.5 |
| Darunavir | 3.7 | 0.1 |
| Tipranavir | 0.5 | 0.4 |
| Efavirenz | 50.4 | 3.0 |
| Nevirapine | 29.1 | 3.2 |
| Delavirdine | 3.9 | 2.1 |
| Entry inhibitors | 3.7 | 1.4 |
ARV, antiretroviral; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.